Mitochondria-targeted resveratrol derivatives act as cytotoxic pro-oxidants

Resveratrol derivatives bearing an O-linked mitochondria-targeting 4-triphenylphosphoniumbutyl group at either position 3 or position 4' are prooxidant and cytotoxic for cultured cells, selectively killing fast-growing cells when supplied in the low μM range. Resveratrol is essentially without...

Full description

Saved in:
Bibliographic Details
Published inCurrent pharmaceutical design Vol. 20; no. 2; p. 172
Main Authors Sassi, Nicola, Mattarei, Andrea, Azzolini, Michele, Bernardi, Paolo, Szabo', Ildiko', Paradisi, Cristina, Zoratti, Mario, Biasutto, Lucia
Format Journal Article
LanguageEnglish
Published United Arab Emirates 01.01.2014
Subjects
Online AccessGet more information

Cover

Loading…
Abstract Resveratrol derivatives bearing an O-linked mitochondria-targeting 4-triphenylphosphoniumbutyl group at either position 3 or position 4' are prooxidant and cytotoxic for cultured cells, selectively killing fast-growing cells when supplied in the low μM range. Resveratrol is essentially without effect under these experimental conditions, while the cytotoxicity of the mitochondriotropic derivatives increases if they are methylated on the remaining hydroxyls. Experiments with Bax(-/-)/Bak(-/-) cells and a pan-caspase inhibitor show that cell death is mostly of the necrotic type. Cytotoxicity is due to ROS produced upon accumulation of the compounds into mitochondria, and specifically to H2O2, since externally added membrane-permeant catalase largely prevents cell death while superoxide dismutase potentiates toxicity. The mitochondriotropic compounds cause ROS-independent depolarization of in situ mitochondria. Effectiveness is increased if resveratrol hydroxyls are acetylated or methylated; this excludes the involvement of autooxidation of the polyphenolic nucleus and a protonophoric cycle as the causes of ROS generation and of depolarization, respectively. Resveratrol-triphenylphosphonium conjugates may thus represent a new class of chemotherapeutic agents, redox-active "mitocans", whose mechanisms of action and in vivo activity are worthy of further investigation.
AbstractList Resveratrol derivatives bearing an O-linked mitochondria-targeting 4-triphenylphosphoniumbutyl group at either position 3 or position 4' are prooxidant and cytotoxic for cultured cells, selectively killing fast-growing cells when supplied in the low μM range. Resveratrol is essentially without effect under these experimental conditions, while the cytotoxicity of the mitochondriotropic derivatives increases if they are methylated on the remaining hydroxyls. Experiments with Bax(-/-)/Bak(-/-) cells and a pan-caspase inhibitor show that cell death is mostly of the necrotic type. Cytotoxicity is due to ROS produced upon accumulation of the compounds into mitochondria, and specifically to H2O2, since externally added membrane-permeant catalase largely prevents cell death while superoxide dismutase potentiates toxicity. The mitochondriotropic compounds cause ROS-independent depolarization of in situ mitochondria. Effectiveness is increased if resveratrol hydroxyls are acetylated or methylated; this excludes the involvement of autooxidation of the polyphenolic nucleus and a protonophoric cycle as the causes of ROS generation and of depolarization, respectively. Resveratrol-triphenylphosphonium conjugates may thus represent a new class of chemotherapeutic agents, redox-active "mitocans", whose mechanisms of action and in vivo activity are worthy of further investigation.
Author Paradisi, Cristina
Azzolini, Michele
Zoratti, Mario
Mattarei, Andrea
Szabo', Ildiko'
Sassi, Nicola
Biasutto, Lucia
Bernardi, Paolo
Author_xml – sequence: 1
  givenname: Nicola
  surname: Sassi
  fullname: Sassi, Nicola
– sequence: 2
  givenname: Andrea
  surname: Mattarei
  fullname: Mattarei, Andrea
– sequence: 3
  givenname: Michele
  surname: Azzolini
  fullname: Azzolini, Michele
– sequence: 4
  givenname: Paolo
  surname: Bernardi
  fullname: Bernardi, Paolo
– sequence: 5
  givenname: Ildiko'
  surname: Szabo'
  fullname: Szabo', Ildiko'
– sequence: 6
  givenname: Cristina
  surname: Paradisi
  fullname: Paradisi, Cristina
– sequence: 7
  givenname: Mario
  surname: Zoratti
  fullname: Zoratti, Mario
– sequence: 8
  givenname: Lucia
  surname: Biasutto
  fullname: Biasutto, Lucia
  email: lucia.biasutto@unipd.it
  organization: CNR Institute of Neuroscience, c/o Dept. of Biomedical Sciences, Viale Giuseppe Colombo 3, 35121 Padova, Italy. lucia.biasutto@unipd.it
BackLink https://www.ncbi.nlm.nih.gov/pubmed/23701548$$D View this record in MEDLINE/PubMed
BookMark eNo1j8lKBDEURYMo9qB_IJIfKM1LUhmW0jhhixtdNy9DaUl3pUhiYf-9DerdnLM6cBfkeEhDJOQC2BUHLa9BGFDADYAAexhjQh6RORgtGsmNmpFFKZ-MAbcgT8mMC82glWZOnp77mvxHGkLusamY32ONgeZYppix5rSlIeZ-wtpPsVD0lWKhfl9TTd-9p2NOzUECDrWckZMOtyWe_3FJ3u5uX1cPzfrl_nF1s26cFLw2WgRl0XRGKeTcOCG5Q2jRgmbYGhW5tBhCEMCUMa12zrNO-9ajQKNt4Ety-dsdv9wuhs2Y-x3m_eb_Ff8Bon5Qww
CitedBy_id crossref_primary_10_1038_cddis_2015_263
crossref_primary_10_3390_cancers15030666
crossref_primary_10_1007_s12010_022_04252_5
crossref_primary_10_1089_ars_2017_7404
crossref_primary_10_1016_j_isci_2023_108659
crossref_primary_10_1021_acs_chemrev_7b00042
crossref_primary_10_15252_embr_201643354
crossref_primary_10_3390_molecules25225443
crossref_primary_10_1080_14756366_2018_1442831
crossref_primary_10_1016_j_bmcl_2020_127234
crossref_primary_10_1021_acsomega_1c05515
crossref_primary_10_1002_JLB_5VMR0818_330RR
crossref_primary_10_3390_antiox8080244
crossref_primary_10_1016_j_bbagen_2016_01_017
crossref_primary_10_1016_j_bcp_2023_115953
crossref_primary_10_3390_cancers11070916
crossref_primary_10_1039_C9MD00572B
crossref_primary_10_3390_molecules28031057
crossref_primary_10_1021_acs_jmedchem_7b00679
crossref_primary_10_1111_jfbc_13008
crossref_primary_10_3390_molecules27031001
crossref_primary_10_3390_toxics5040038
crossref_primary_10_1111_nyas_13401
crossref_primary_10_1016_j_phrs_2017_07_016
crossref_primary_10_1016_j_bbabio_2014_06_010
crossref_primary_10_3390_pharmaceutics13081205
crossref_primary_10_1016_j_ejmech_2019_07_060
crossref_primary_10_1016_j_biocel_2018_02_007
crossref_primary_10_2147_IJN_S303832
crossref_primary_10_1021_acs_jmedchem_8b01052
crossref_primary_10_3390_antibiotics12020401
crossref_primary_10_1016_j_phrs_2021_105959
crossref_primary_10_1016_j_canlet_2015_07_004
crossref_primary_10_1111_bph_13954
crossref_primary_10_1371_journal_pone_0144290
crossref_primary_10_1158_1940_6207_CAPR_20_0425
crossref_primary_10_3390_ijms23105572
crossref_primary_10_1038_srep08088
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.2174/13816128113199990034
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1873-4286
ExternalDocumentID 23701548
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
.5.
0R~
29F
36B
3V.
4.4
53G
5GY
69Q
7X7
88E
8AO
8FI
8FJ
8R4
8R5
AAEGP
ABEEF
ABJNI
ABUWG
ABVDF
ACGFO
ACGFS
ACITR
ACIWK
ACPRK
ADBBV
AENEX
AFKRA
AFRAH
AFUQM
AGJNZ
AHMBA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ANTIV
BENPR
BPHCQ
BVXVI
C1A
CCPQU
CGR
CS3
CUY
CVF
DU5
EBS
ECM
EIF
EJD
F5P
FYUFA
GH2
HMCUK
HZ~
IPNFZ
KCGFV
KFI
M1P
NPM
O9-
P2P
PQQKQ
PROAC
PSQYO
Q2X
RIG
UKHRP
ID FETCH-LOGICAL-b432t-73d69a8f866a228b342ba15a9170a586e249addd31068857bbc0f7c5ca3a879d2
IngestDate Sat Sep 28 08:34:41 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-b432t-73d69a8f866a228b342ba15a9170a586e249addd31068857bbc0f7c5ca3a879d2
PMID 23701548
ParticipantIDs pubmed_primary_23701548
PublicationCentury 2000
PublicationDate 2014-01-01
PublicationDateYYYYMMDD 2014-01-01
PublicationDate_xml – month: 01
  year: 2014
  text: 2014-01-01
  day: 01
PublicationDecade 2010
PublicationPlace United Arab Emirates
PublicationPlace_xml – name: United Arab Emirates
PublicationTitle Current pharmaceutical design
PublicationTitleAlternate Curr Pharm Des
PublicationYear 2014
SSID ssj0012914
Score 2.3477643
Snippet Resveratrol derivatives bearing an O-linked mitochondria-targeting 4-triphenylphosphoniumbutyl group at either position 3 or position 4' are prooxidant and...
SourceID pubmed
SourceType Index Database
StartPage 172
SubjectTerms Animals
bcl-2 Homologous Antagonist-Killer Protein - genetics
bcl-2-Associated X Protein - genetics
Cell Death - drug effects
Cells, Cultured
Dose-Response Relationship, Drug
Gene Knockout Techniques
Hydrogen Peroxide - metabolism
Mice
Mitochondria - drug effects
Mitochondria - metabolism
Necrosis - pathology
Oxidants - administration & dosage
Oxidants - chemistry
Oxidants - pharmacology
Oxidation-Reduction
Reactive Oxygen Species - metabolism
Resveratrol
Stilbenes - administration & dosage
Stilbenes - chemistry
Stilbenes - pharmacology
Title Mitochondria-targeted resveratrol derivatives act as cytotoxic pro-oxidants
URI https://www.ncbi.nlm.nih.gov/pubmed/23701548
Volume 20
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Li9swEBbZ9tJL6ftddCh7WrWxLEvycSktS0uXhWZhb4seYxpok9CYpcmhv70zluNoQ0ofF2Os4Ah_n8ea0cw3jL1qDHivIiW1AwhlfCG8Bi10VE1oJIBK2Ran-uRcfbioLkajn3l1Setfh_XeupL_QRWvIa5UJfsPyA43xQt4jvjiERHG419h_AlfRzRfs4j_JVJON1A1yvKKpJIpAz3iNK46be8lyWZQV5mwauft_Mc0UG6WwJPoejmnQbGg12xafLkW747Xkj0-46p7OnBpMO7UP9x9h-mQLDmMHK_X1CBouknWh6_bDX0KSiJT05IWzXEeiyhUFouAZD-tKQV6NDo3sHKcEUlm1rJIXXt2rTh5SRRQoD1N2ugrStJKoJCryn-OWCy-dcjK0nSu159Hd7S1N0MH7MBYspKnFOvp96BkXahUbEkTerNvOiQl3d9ixy3plieTO-x271fw40SSu2wEs3vs8CwhuDrik22d3fKIH_KzrWT56j77uJdJPGMSz5jEkUncLfnAJJ4z6QE7f_9u8vZE9G02hFelbIUpo66dbazWTkrrSyW9KyqHjvzYVVYDeuj4FYzoCGhrK-N9GDcmVMGVzpo6yofsxmw-g8eMQzA6mOi8q2oFlj4GDVRNbaVTui7rJ-xRekiXi6Slcrl5fE9_O_KM3dpS7Tm72eDLCy9wJdj6lx1gvwBYSmER
link.rule.ids 783
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mitochondria-targeted+resveratrol+derivatives+act+as+cytotoxic+pro-oxidants&rft.jtitle=Current+pharmaceutical+design&rft.au=Sassi%2C+Nicola&rft.au=Mattarei%2C+Andrea&rft.au=Azzolini%2C+Michele&rft.au=Bernardi%2C+Paolo&rft.date=2014-01-01&rft.eissn=1873-4286&rft.volume=20&rft.issue=2&rft.spage=172&rft_id=info:doi/10.2174%2F13816128113199990034&rft_id=info%3Apmid%2F23701548&rft_id=info%3Apmid%2F23701548&rft.externalDocID=23701548